AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: liver enzymes activity assessment
Description: activity of:~* alanine transaminase (ALT) \[U/l\];~* aspartate transaminase (AST) \[U/l\];~* alkaline phosphatase (ALP) \[U/l\]~were assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: total protein and albumin
Description: * total protein (TP) \[g/dl\];~* albumin (ALB) \[g/dl\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: creatinine and urea
Description: * creatinine in the serum \[mg/dl\] - the assay is based on the reaction of creatinine with sodium picrate as described by Jaffe (Jaffes' colorimetric method) - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA;~* urea \[mg/dl\] in the serum - was assessed by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (2)
Description: myeloperoxidase (MPO) \[ng/ml\] in the serum- was determined by the ELISA method using the Quantikine Human MPO test by R\&D Systems kit, Canada.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (3) sRAGE
Description: soluble receptor for advanced glycation end products (sRAGE) \[µg/mg protein\] in the serum was tested with enzymatic immunoassay (Quantikine ELISA) using R\&D Systems kit, Canada.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: selected parameters of oxidative stress (4) MG, CEL, carbamyl protein groups
Description: * methylglyoxal (MG) \[µg/mg protein\];~* carboxyethyle(lysine) (CEL) \[µg/mg protein\];~* carbamyl protein groups \[µg/mg protein\] were assessed in the serum by competitive enzyme immunoassay (competitive ELISA) using kits from Cell Biolabs Inc, USA.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: selected electrolytes assessment
Description: * potassium (K) \[mmol/l\];~* sodium (Na) \[mmol/l\];~* magnesium (Mg) \[mg/dL\]~were assessed in the serum by routine techniques using Cobas Integra 400 plus biochemical analyzer by Roche Diagnostics, USA.
Study NCT05214872 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: NT-pro-brain natriuretic peptide (NT-proBNP)
Description: NT-proBNP \[fmol/ml\] - was analyzed in the serum by enzyme immunoassay using the Nt-proBNP kit from Biomedica, Slovakia.
Study NCT05214872 — intervention group
Intervention type: OTHER
Intervention: estimated glomerular filtration rate (eGFR) calculation
Description: eGFR \[ml/min/1.73m\^2\] - according to the Kidney Disease: Improving Global Outcomes (KDIGO) 2012 recommendations was calculated based on the Modification of Diet in Renal Disease (MDRD) formula: eGFR = 186 x \[creatinine concentration in mg/dl\] - 1.154 x \[age in years\] - 0.203 x \[0.724\] for the female gender.
Study NCT01346826 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard 2 hours-infusion
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 2 hours-infusion group, patients get 5 mg/kg infliximab infusion for 2 hours. Total infusion number after randomization is 7.
Study NCT01346826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accelerated 1 hour-infusion
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 1 hour-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. Total infusion number after randomization is 7.
Study NCT01346826 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Accelerated 30 minutes-infusion
Description: Patients without any infusion reactions during more than 4 infusions for 2 hours are randomized to one of three study groups.~After randomization to 30 minutes-infusion group, patients get 5 mg/kg infliximab infusion for 1 hour. If any infusion reactions do not develop during 2 infusions for 1 hour, patients get further 5 mg/kg infliximab infusion for 30 minutes. The total number of 30 minutes-infusion is 5.
Study NCT02906150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thymalfasin (Thymosin alpha 1, Ta1)
Description: Patients will be randomized to Thymosin alpha 1 plus SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
Study NCT02906150 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SoC (chemotherapy and platinum agent)
Description: Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
Study NCT02906150 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SoC (chemotherapy and platinum agent)
Description: Patients will be randomized to SoC for treatment duration of 12 months. All patients will be followed for approximately 12 months or until the total number of PFS events required will be observed.
Study NCT02283060 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Stribild
Description: To be administered orally, once daily with food.
Study NCT02283060 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Atripla
Description: To be administered orally, once daily at bedtime on an empty stomach
Study NCT01401751 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Hypoglycemia-Hyperglycemia Minimizer System
Description: Hypoglycemia-Hyperglycemia Minimizer System, consisting of an subcutaneous insulin infusion pump, subcutaneous continuous glucose monitoring system, and a controller algorithm
Study NCT02910648 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Modified Go/No-Go Task
Description: Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
Study NCT02910648 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Modified Go/No-Go Task
Description: Participants in the experimental group and control sham sound cues group will complete a computerized training task to facilitate learning to respond (press a computer key) to healthy food stimuli and to inhibit responses (not press a computer key) to unhealthy food stimuli. Participants in the control sham go/no-go group will complete a similar task with common office supplies (approach) and tools (inhibit). All participants will also complete a 24 hour dietary recall as described below.
Study NCT01348867 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Structured care led by a nurse consultant
Description: For the intervention group, patients will be followed up according to the following protocol. The structured care team consists of:~i) Diabetes Nurse Consultant to reinforce compliance; educate patients on insulin injection techniques and reinforce self-care including self blood glucose monitoring and lifestyle interventions, titration of medication.~ii) Technical Service Assistance to remind patients to take medications and/or give insulin injection, monitor blood glucose as prescribed, attend their next clinic appointment, encourage patients to report all side effects, self initiated change in regimen or concerns to diabetes nurse consultant and/or their doctors at the next follow up visit.
Study NCT02367261 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SPI implant
Description: SPI implant - the original spiral implant
Study NCT03036163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 40 mg
Description: 40 mg of PBTZ169 (1 capsule) orally once in fasting state
Study NCT03036163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 80 mg
Description: 80 mg of PBTZ169 (2 capsules 40 mg) orally once in fasting state
Study NCT03036163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 160 mg
Description: 160 mg of PBTZ169 (4 capsules 40 mg) orally once in fasting state
Study NCT03036163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 320 mg
Description: 320 mg of PBTZ169 (8 capsules 40 mg) orally once in fasting state
Study NCT03036163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 640 mg
Description: 640 mg of PBTZ169 (16 capsules 40 mg) orally once in fasting state
Study NCT03036163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 320 mg (multiple administration)
Description: 320 mg of PBTZ169 (8 capsules 40 mg) orally once per day in fasting state for 14 days
Study NCT03036163 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBTZ169 - 640 mg (multiple administration)
Description: 640 mg of PBTZ169 (16 capsules 40 mg) orally once per day in fasting state for 14 days
Study NCT02156713 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CIMT Camp
Study NCT00052468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TCG
Study NCT00052468 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TC
Study NCT06011590 — intervention group
Intervention type: OTHER
Intervention: No intervention.
Description: No intervention.
Study NCT00740792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone propionate
Description: fluticasone propionate 200 mcg one spray per nostril BID
Study NCT00740792 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo one spray per nostril BID
Study NCT04553029 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: This is a cross-sectional survey study evaluating prevalence, severity and associated factors in women with moderate-to-severe menopause-related vasomotor symptoms (MR-VMS).
Study NCT03584698 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol 100Mcg Tab
Description: women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
Study NCT03584698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Misoprostol 100Mcg Tab
Description: women will receive misoprostol 100 mcg (Misotac, Sigma Pharmaceuticals, Egypt) vaginally applied every 6 hours till cervical dilatation.
Study NCT03584698 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evening Primrose Oil 1000 MG
Description: women will receive 4 capsules evening primrose oil 1000 mg (Primrose plus, Ema Pharm, Egypt) vaginally applied every 6 hours till cervical dilatation.
Study NCT02313428 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Topical Oxygen Chamber for Extremities
Description: Surrounds a limb and applies oxygen topically at a pressure slightly greater than atmospheric pressure to aid healing of chronic skin ulcers
Study NCT01571505 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IPV vaccination
Description: Randomized IPV or OPV to children aged at 39weeks.
Study NCT04309006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG and customized healing abutment
Description: screw- retained customized healing abutment
Study NCT04309006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG and customized healing abutment
Description: screw- retained customized healing abutment
Study NCT04309006 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CTG and conventional healing abutment
Description: conventional healing abutment
Study NCT04309006 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: CTG and conventional healing abutment
Description: conventional healing abutment
Study NCT04410003 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Fecal microbial transplant
Description: Fecal microbial transplant
Study NCT04410003 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Fecal microbial transplant
Description: Fecal microbial transplant
Study NCT01571505 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: IPV vaccination
Description: Randomized IPV or OPV to children aged at 39weeks.
Study NCT00564122 — intervention group
Intervention type: DEVICE
Intervention: Artificially-Intelligent Stethoscope
Description: After subjects' medical visits are complete, the heart sounds of all subjects will be recorded and assessed by an artificially-intelligent stethoscope. Attempts will be made to make satisfactory 20-second recordings from a total of eight positions on the chest with the patient in supine and upright positions.
Study NCT00564122 — intervention group
Intervention type: OTHER
Intervention: Physical Examination
Description: A Pediatric Cardiologist will examine each subject to the extent needed to make clinical assessments. This represents the ordinary standard-of-care.
Study NCT02477618 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SAGE-547
Study NCT02477618 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03961165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Butylscopolamine Bromide 20 MG/ML
Description: 1 mL Butylscopolamine Bromide 20 mg/mL i.v. Single dose.
Study NCT03961165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sodium Chloride 9mg/mL
Description: 1 mL Sodium Chloride 9 mg/mL i.v. Single dose.
Study NCT04450108 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Vivatmo pro FeNO Test
Description: Breath gas analysis
Study NCT03375944 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Rehabilitation
Description: The purpose of this work package is to evaluate short- and long-term clinical effects of optimal, continuous and regularly controlled tele-rehabilitation, which is based on exercise training, intensive dietary and educational program focused on lifestyle and risk factors modification. The main expectations of OCR is to normalize annual mortality to the level of the low risk healthy population.
Study NCT03311438 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Oral health intervention program
Description: Intervention: All parents were encouraged to brush their children's teeth twice a day, with adjusted amount of fluoride toothpaste according to age. Additional fluoride tablets with dose according to age were recommended from two years of age. The children's parents were given written information about the importance and benefits of optimal oral hygiene and explaining the link to infective endocarditis. A pamphlet, lift the lip program, with instruction of looking for early signs of tooth decay, how to intervene and contact local Public Dental Service (PDS) clinic. Dietary advice was also given. The child's responsible dentist or dental hygienist at the local PDS was contacted with information about the project and the findings from examination.
Study NCT01181206 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intervention Arm 1: Covering with approved abdominal 3M™ Steri-Drape™ Wound Edge Protector Intervention Arm 2: Covering with standard woven swabs
Study NCT03408717 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires including Pain catastrophizing scale (PCS), Central Sensitisation Inventory (CSI), Coping Strategies Questionnaire-Revised (CSQ-R), Brief Symptom Inventory-18 (BSI-18), Perceived Stress Scale (PSS), EQ-5D-3L and Eysenck Personality Questionnaire (EPQ) will be administered to the patient.
Study NCT03408717 — intervention group
Intervention type: OTHER
Intervention: Mechanical Temporal Summation assessment
Description: A 180 gram von Frey filament is applied on the subject's forearm. Patient will then be asked to rate the pinprick pain score on a verbal rating scale, 0-100. Following this, 10 consecutive touches at random locations are applied with a 1 second interstimulus interval and within a 1 cm diameter circle. The patient will then be asked to rate the 10th pain score (0-100). The Mechanical Temporal Summation Score is obtained by the difference between the 11th pain score and the 1st pain score. If the score is greater than zero, the patient is implied to have presence of Mechanical Temporal Summation.
Study NCT03408717 — intervention group
Intervention type: OTHER
Intervention: Pain threshold assessment
Description: Pressure is applied 90 degree straight down force on the subject's right/left centre of the trapezius muscle using an algometer, with a speed of pressure \~ 1kgf/s. The above procedure is then repeated 3 times at each site (left/right) which is indicated on the pressure mark with each time having the reading recorded. When patient shows no response ≥ 6kgf, the threshold is recorded as 6kgf. The patient upon feeling pain will say stop or raise the hand to terminate the test. The mean value is obtained by averaging the readings and will then be recorded as the threshold estimate.
Study NCT02127645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: SRT-TEM
Description: SRT-TEM underwent 25 Gy RT followed by TEM
Study NCT02127645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: LRT-TEM
Description: TEM following 46 Gy RT
Study NCT02127645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transanal Endoscopic Microsurgery (TEM)
Description: Transanal Endoscopic Microsurgery (TEM)
Study NCT02127645 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Mesorectal Excision (TME)
Description: Laparoscopic Total Mesorectal Excision
Study NCT03915535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Eicosapentaenoic acid + Docosahexaenoic acid
Description: Monoglyceride Omega-3 fish oils
Study NCT03915535 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Eicosapentaenoic acid
Description: Monoglyceride Omega-3 fish oil
Study NCT02494076 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EzPAP
Study NCT02494076 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Standard Care
Study NCT01945593 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BAX855
Description: Antihemophilic Factor (Recombinant), PEGylated
Study NCT03533803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Indomethacin 100Mg Suppository
Description: Indomethacin 100Mg Suppository will be given 1 to 2 hours before embryo transfer in cases with difficult mock embryo transfer in the active comparator group.
Study NCT03533803 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: IVF/ICSI
Description: patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
Study NCT03533803 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: IVF/ICSI
Description: patients received induction with the long agonist stimulation protocol. Followed by ovum pickup and embryo transfer. Only those with difficult mock embryo transfer will be recruited in this study.
Study NCT02001649 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: SNP Genotyping
Description: Individuals were genotyped at a total 96 SNP from 15 candidate gene
Study NCT02001649 — intervention group
Intervention type: GENETIC
Group type: OTHER
Intervention: SNP genotyping
Study NCT03520088 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Inferior mesenteric Vein dissection
Description: Dissection of the Inferior mesenteric Vein first, and go down to the Artery during the total mesorectal excision
Study NCT03520088 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Inferior mesenteric Artery dissection
Description: Dissection of the Inferior mesenteric Artery directly in the total mesorectal excision
Study NCT01291043 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Shiatsu
Description: 8-week treatment with two Shiatsu sessions per week (50-minute duration)
Study NCT03469258 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Zenpep is a combination of three enzymes (proteins). These enzymes are normally produced by the pancreas and are important in the digestion of fats, proteins, and sugars. Zenpep is used to replace these enzymes when the body does not have enough of its own as a result of surgery and/or pancreatic cancer.
Study NCT03865940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: 6 mL of 1% lidocaine
Study NCT03865940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Guanfacine
Description: 250 mcg
Study NCT00627523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genotropin (PN-180,307) Somatropin
Description: Injectable Genotropin
Study NCT00627523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Control-no treatment
Description: Control-no treatment
Study NCT02367664 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 0.5ml experimental vaccine on day 0,7 Vero cell-derived inactivated Japanese Encephalitis vaccine
Description: Vero cell-derived inactivated Japanese Encephalitis vaccine produced by Shandong Hengye Biotech Co., Ltd./0.5ml, two doses with 7 days interval, a booster dose 12 months after the first dose